leisure time -WSS

leisure time

author：comprehensive 2025-09-27 09:58:34 - browse：54

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： As health system earnings go up, health insurance stocks go down

hotspot

WSS

At flashy new research hub, AstraZeneca lays out ambitious growth goals

Citing H5N1 threat, CDC urges peak flu monitoring this summer

Bird flu surveillance in wastewater gets boost from consortium

Primary care doctor shortage won't be solved by free med school tuition

Warren pushes Witty on UnitedHealth's control over physicians

Listen: A conversation with researcher Kevin Esvelt on biosecurity

Wikipedia

leisure time

Wikipedia

Drug repurposing or repositioning? The language matters

BIO to announce reorganization, senior leaders expected to depart

How one medical school became remarkably diverse

GSK’s asthma push continues as drug succeeds in Phase 3 trials

Medical leaders decry Supreme Court decision on affirmative action

Listen: More tumult at BIO & coercive care for sickle cell patients

Jerome Adams on the need for new antivirals for Covid

Digital health: a case of mistaken identity

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

explore

Cue Health, Covid

Investigation reveals sickle cell patients pressured into sterilizations

For longer

ASCO eve: Let’s set the table for this year's meeting

Has Bernie Sanders reached the limit of his pharma bullying effort?

Crowdfunding for medical bills sidesteps core problem, author says

hotspot

hotspot

hotspot

explore